CC-95266

· Juno Therapeutics, a subsidiary of Celgene

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CC-95266, covering 2026-02-09 to 2026-02-09. Get the full timeline:

Most recent: Clinical Trial Update: A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma [Phase 1]